| Entry |
| ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Name | Clomipramine hydrochloride (JP18/USP); Anafranil (TN) | ||||||||||
| Product | ANAFRANIL (SpecGx LLC), CLOMIPRAMINE HYDROCHLORIDE (SpecGx LLC) | ||||||||||
| Generic | CLOMIPRAMINE HCL (Amneal Pharmaceuticals NY LLC), CLOMIPRAMINE HYDROCHLORIDE (JUBILANT CADISTA PHARMACEUTICALS), CLOMIPRAMINE HYDROCHLORIDE (Ajanta Pharma USA), CLOMIPRAMINE HYDROCHLORIDE (Alembic Pharmaceuticals), CLOMIPRAMINE HYDROCHLORIDE (Alembic Pharmaceuticals Limited), CLOMIPRAMINE HYDROCHLORIDE (American Health Packaging), CLOMIPRAMINE HYDROCHLORIDE (Bryant Ranch Prepack), CLOMIPRAMINE HYDROCHLORIDE (Cadila Healthcare Limited), CLOMIPRAMINE HYDROCHLORIDE (Golden State Medical Supply), CLOMIPRAMINE HYDROCHLORIDE (Golden State Medical Supply), CLOMIPRAMINE HYDROCHLORIDE (Golden State Medical Supply), CLOMIPRAMINE HYDROCHLORIDE (Leading Pharma), CLOMIPRAMINE HYDROCHLORIDE (Lifestar Pharma LLC), CLOMIPRAMINE HYDROCHLORIDE (Major Pharmaceuticals), CLOMIPRAMINE HYDROCHLORIDE (Marlex Pharmaceuticals), CLOMIPRAMINE HYDROCHLORIDE (Micro Labs Limited), CLOMIPRAMINE HYDROCHLORIDE (Mylan Pharmaceuticals), CLOMIPRAMINE HYDROCHLORIDE (Northstar Rx LLC.), CLOMIPRAMINE HYDROCHLORIDE (Proficient Rx LP), CLOMIPRAMINE HYDROCHLORIDE (Rising Pharma Holdings), CLOMIPRAMINE HYDROCHLORIDE (Sandoz), CLOMIPRAMINE HYDROCHLORIDE (Taro Pharmaceuticals U.S.A.), CLOMIPRAMINE HYDROCHLORIDE (TruPharma LLC), CLOMIPRAMINE HYDROCHLORIDE (Upsher-Smith Laboratories), CLOMIPRAMINE HYDROCHLORIDE (VGYAAN Pharmaceuticals LLC), CLOMIPRAMINE HYDROCHLORIDE (Zydus Pharmaceuticals (USA)), CLOMIPRAMINE HYDROCHLORIDE (Lupin Pharmaceuticals) | ||||||||||
| Formula | C19H23ClN2. HCl | ||||||||||
| Exact mass | 350.1317 | ||||||||||
| Mol weight | 351.3133 | ||||||||||
| Structure |  | ||||||||||
| Simcomp | |||||||||||
| Class | Neuropsychiatric agent DG01730 Non-selective monoamine reuptake inhibitor DG01728 Tricyclic antidepressant Metabolizing enzyme substrate DG01892 CYP1A2 substrate DG01639 CYP2C19 substrate DG01644 CYP2D6 substrate DG01633 CYP3A/CYP3A4 substrate DG02913 CYP3A4 substrate | ||||||||||
| Remark |
| ||||||||||
| Efficacy | Antidepressant, Serotonin-noradrenaline reuptake inhibitor (SNRI) | ||||||||||
| Disease | Obsessive-compulsive disorder [DS:H01450] | ||||||||||
| Target | SLC6A4 (HTT) [HSA:6532] [KO:K05037] SLC6A2 (NAT1) [HSA:6530] [KO:K05035] | ||||||||||
| Pathway |
| ||||||||||
| Metabolism | Enzyme: CYP2D6 [HSA:1565]; CYP1A2 [HSA:1544], CYP3A4 [HSA:1576], CYP2C19 [HSA:1557] | ||||||||||
| Interaction | |||||||||||
| Structure map |
| ||||||||||
| Brite | Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] N NERVOUS SYSTEM N06 PSYCHOANALEPTICS N06A ANTIDEPRESSANTS N06AA Non-selective monoamine reuptake inhibitors N06AA04 Clomipramine D00811 Clomipramine hydrochloride (JP18/USP) <JP/US> USP drug classification [BR:br08302] Antidepressants Tricyclics Clomipramine D00811 Clomipramine hydrochloride (JP18/USP) Therapeutic category of drugs in Japan [BR:br08301] 1 Agents affecting nervous system and sensory organs 11 Agents affecting central nervous system 117 Psychotropics 1174 Imipramines D00811 Clomipramine hydrochloride (JP18/USP) 1179 Others D00811 Clomipramine hydrochloride (JP18/USP) Drug groups [BR:br08330] Neuropsychiatric agent DG01730 Non-selective monoamine reuptake inhibitor DG00929 Clomipramine D00811 Clomipramine hydrochloride DG01728 Tricyclic antidepressant DG00929 Clomipramine D00811 Clomipramine hydrochloride Metabolizing enzyme substrate DG01892 CYP1A2 substrate DG00929 Clomipramine D00811 Clomipramine hydrochloride DG01639 CYP2C19 substrate DG00929 Clomipramine D00811 Clomipramine hydrochloride DG01644 CYP2D6 substrate DG00929 Clomipramine D00811 Clomipramine hydrochloride DG01633 CYP3A/CYP3A4 substrate DG02913 CYP3A4 substrate DG00929 Clomipramine D00811 Clomipramine hydrochloride Drug classes [BR:br08332] Neuropsychiatric agent DG01730 Non-selective monoamine reuptake inhibitor D00811 Clomipramine hydrochloride Target-based classification of drugs [BR:br08310] Transporters Solute carrier family SLC6 SLC6A2 (NAT1) D00811 Clomipramine hydrochloride (JP18/USP) <JP/US> SLC6A4 (HTT) D00811 Clomipramine hydrochloride (JP18/USP) <JP/US> Drugs listed in the Japanese Pharmacopoeia [BR:br08311] Chemicals D00811 Clomipramine hydrochloride D00811 Clomipramine hydrochloride tablets Drug metabolizing enzymes and transporters [br08309.html] Drug metabolizing enzymes D00811 Pharmacogenomic biomarkers [br08341.html] Polymorphisms and mutations affecting drug response D00811 Drug groups [BR:br08330] Neuropsychiatric agent DG01730 Non-selective monoamine reuptake inhibitor DG00929 Clomipramine DG01728 Tricyclic antidepressant DG00929 Clomipramine Metabolizing enzyme substrate DG01892 CYP1A2 substrate DG00929 Clomipramine DG01639 CYP2C19 substrate DG00929 Clomipramine DG01644 CYP2D6 substrate DG00929 Clomipramine DG01633 CYP3A/CYP3A4 substrate DG02913 CYP3A4 substrate DG00929 Clomipramine | ||||||||||
| Other DBs |
| ||||||||||
| KCF data | ATOM 23 1 C1x C 18.7534 -14.2894 2 C8y C 17.9113 -13.1798 3 C8y C 18.2465 -11.8230 4 N1y N 19.5075 -11.2449 5 C1x C 20.1592 -14.3146 6 C8y C 20.7611 -11.8672 7 C8y C 21.0476 -13.2359 8 C8x C 17.2394 -10.8546 9 C8y C 15.8974 -11.2427 10 C8x C 15.5622 -12.5995 11 C8x C 16.5693 -13.5676 12 C8x C 22.3788 -13.6730 13 C8x C 23.4230 -12.7386 14 C8x C 23.1366 -11.3699 15 C8x C 21.8052 -10.9328 16 X Cl 14.8980 -10.2821 17 C1b C 19.5292 -9.8700 18 C1b C 20.7532 -9.1889 19 C1b C 21.9216 -9.8884 20 N1c N 23.1437 -9.2083 21 C1a C 24.3784 -9.9469 22 C1a C 23.1657 -7.8400 23 X Cl 26.3900 -12.4600 BOND 24 1 3 4 1 2 1 5 1 3 4 6 1 4 2 3 1 5 5 7 1 6 1 2 1 7 6 7 1 8 3 8 2 9 8 9 1 10 9 10 2 11 10 11 1 12 2 11 2 13 7 12 2 14 12 13 1 15 13 14 2 16 14 15 1 17 6 15 2 18 9 16 1 19 4 17 1 20 17 18 1 21 18 19 1 22 19 20 1 23 20 21 1 24 20 22 1 |